Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Cure Connections

Following a discussion on where to find reliable information on chronic lymphocytic leukemia (CLL) and treatment, participants share their closing thoughts.
Participants highlight the importance of proper support and communication while receiving therapy for chronic lymphocytic leukemia (CLL).
 
Considerations for what happens when a patient progresses with chronic lymphocytic leukemia (CLL).
 
Shared insight on the long-term nature of treatment for chronic lymphocytic leukemia (CLL).
 
More

Cure Expert Connections

Perspectives on treatment decision-making in cutaneous squamous cell carcinoma, particularly regarding who is involved in selecting therapy.
Dr. Todd Schlesinger shares his experience with cemiplimab, an immunotherapy agent used to treat cutaneous squamous cell carcinoma.
 
Considerations for the use of immunotherapy, a novel approach to treatment, in patients with cutaneous squamous cell carcinoma.
 
A comprehensive review of both surgical and systemic treatment options for cutaneous squamous cell carcinoma.
More

Cure TV

Bradley McGregor, M.D.
Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.
Katie Kosko and Jessica Skarzynski
Here’s a look at what’s inside our 2020 Winter issue.
Jessica Skarzynski
Treatments for Renal Cell Carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.
Dr. Thomas Powles
The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.
More

Cure Speaking Out

Kristie L. Kahl and Lisa Schlager
Lisa Schlager, vice president of public policy at FORCE: Facing Our Risk Empowered, sits down with CURE® to discuss genetic mutations in men that are not being addressed.
Kristie L. Kahl and Lisa Schlager
Lisa Schlager, vice president of public policy at FORCE: Facing Our Risk Empowered, discussed the various laws and legislation put into place to protect those who have a genetic predisposition to cancer.
Kristie L. Kahl and Lisa Schlager
Lisa Schlager, vice president of public policy at FORCE: Facing Our Risk Empowered, offered background on the differences between genetic testing and a direct-to-consumer test, and why patients should be careful when using over-the counter genetic tests.
Kristie L. Kahl and Lee Greenberger
Lee Greenberger, chief scientific officer at the Leukemia and Lymphoma Society, discusses the use of immunotherapy in blood cancer treatment.
More
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×